Diligence memo · auto-generated · as of July 2, 2026
Aion Therapeutic Inc.
Aion Therapeutic Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Aion Therapeutic Inc. operates in Biotech / Pharma, based in Vancouver.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aion Therapeutic Inc. has raised $5.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.8M on 2023-12-15.
Most recent recorded round closed around 2023-12-15.
Valuation (modeled)modeled
Provath models Aion Therapeutic Inc. at approximately $39M (range $6.5M–$95M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.5 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 54% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 58% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.